Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/world congress on gastrointestinal cancer, Barcelona, 2022. ESMO Open. 2023;8: 101567. https://doi.org/10.1016/j.esmoop.2023.101567.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317–45. https://doi.org/10.1200/JCO.20.02672.

Article  CAS  PubMed  Google Scholar 

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1.

Article  CAS  PubMed  Google Scholar 

Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960–70. https://doi.org/10.1200/JCO.20.00808.

Article  PubMed  PubMed Central  Google Scholar 

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33:S1401. https://doi.org/10.1016/j.annonc.2022.08.031.

Article  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905. https://doi.org/10.1056/NEJMoa1915745.

Article  CAS  PubMed  Google Scholar 

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–73. https://doi.org/10.1016/j.jhep.2021.11.030.

Article  CAS  PubMed  Google Scholar 

Fulgenzi CAM, D’Alessio A, Airoldi C, Scotti L, Demirtas CO, Gennari A, et al. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials. Eur J Cancer. 2022;174:57–67. https://doi.org/10.1016/j.ejca.2022.06.058.

Article  CAS  PubMed  Google Scholar 

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350: g7647. https://doi.org/10.1136/bmj.g7647.

Article  PubMed  Google Scholar 

Wang BC, Fu C, Lin GH. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data. Front Immunol. 2023;14:1185577. https://doi.org/10.3389/fimmu.2023.1185577.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird’s methodology to perform multivariate random effects meta-analyses. Stat Med. 2010;29:1282–97. https://doi.org/10.1002/sim.3602.

Article  PubMed  Google Scholar 

Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31:3805–20. https://doi.org/10.1002/sim.5453.

Article  PubMed  PubMed Central  Google Scholar 

Combescure C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat Med. 2014;33:2521–37. https://doi.org/10.1002/sim.6111.

Article  PubMed  Google Scholar 

Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, et al. Survival outcomes from atezolizumab plus bevacizumab versus lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol. 2023;149(10):7565–77. https://doi.org/10.1007/s00432-023-04678-2.

Article  CAS  PubMed  Google Scholar 

Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, et al. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study. J Cancer Res Clin Oncol. 2023;149(9):5591–602. https://doi.org/10.1007/s00432-022-04512-1.

Article  CAS  PubMed  Google Scholar 

Su CW, Teng W, Lin PT, Jeng WJ, Chen KA, Hsieh YC, et al. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med. 2023;12:7077–89. https://doi.org/10.1002/cam4.5506.

Article  CAS  PubMed  Google Scholar 

Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, et al. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population. Eur J Cancer. 2023;180:9–20. https://doi.org/10.1016/j.ejca.2022.11.017.

Article  CAS  PubMed  Google Scholar 

Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, et al. Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a propensity score matching analysis. Target Oncol. 2022;17:643–53. https://doi.org/10.1007/s11523-022-00921-x.

Article  PubMed  PubMed Central  Google Scholar 

Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7: 100591. https://doi.org/10.1016/j.esmoop.2022.100591.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al. Does first-line treatment have prognostic impact for unresectable HCC?—atezolizumab plus bevacizumab versus lenvatinib. Cancer Med. 2023;12:325–34. https://doi.org/10.1002/cam4.4854.

Article  CAS  PubMed  Google Scholar 

Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Miyazaki M, et al. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma. Hepatol Res. 2022;52:630–40. https://doi.org/10.1111/hepr.13771.

Article  CAS  PubMed  Google Scholar 

Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, et al. Atezolizumab/bevacizumab vs. lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a real-world, multi-center study. Cancer. 2022;14:1747. https://doi.org/10.3390/cancers14071747.

Article  CAS  Google Scholar 

Laethem JLV, Borbath I, Karwal M, Verslype C, VanVlierberghe H, Kardosh A, et al. 933P Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study. Annal Oncol. 2021;32:S819. https://doi.org/10.1016/j.annonc.2021.08.153.

Article  Google Scholar 

Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40:379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379.

Article  Google Scholar 

Abou-Alfa Ghassan K, Lau G, Kudo M, Chan Stephen L, Kelley Robin K, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2100070.

Article  Google Scholar 

Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22:977–90. https://doi.org/10.1016/S1470-2045(21)00252-7.

Article  CAS  PubMed  Google Scholar 

Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55:113–22. https://doi.org/10.1007/s00535-019-01642-1.

Article  CAS  PubMed  Google Scholar